How many investments has MPM BioImpact made?

MPM BioImpact has 66 tracked investments, 5 of which have exited, including 9 dated in the last 24 months.

What stage does MPM BioImpact invest at?

MPM BioImpact invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.

What is MPM BioImpact's typical check size?

MPM BioImpact typically writes checks of $1M – $15M.

What sectors does MPM BioImpact focus on?

MPM BioImpact focuses on Biotech, Healthtech, Impact & Social Good, Longevity, Mental Health.

Where is MPM BioImpact located?

MPM BioImpact is headquartered in Boston, US.

Does MPM BioImpact lead rounds?

MPM BioImpact has led 4 of the 11 rounds where its role is on record.

Who does MPM BioImpact co-invest with?

MPM BioImpact most often shares deals with Vida Ventures, Astellas Venture Management LLC, Canaan Partners, among 46 tracked co-investors.

MPM BioImpact

Impact investor

Boston · Pre-Seed–Late Stage · 50 people tracked

Also known as MPM ASSET MANAGEMENT LLC · MPM Capital

★ Follow + Add to CRM ⤳ Find an introduction

Find your way into MPM BioImpact

2,183 people in our graph share verified history with the MPM BioImpact team — schools, employers, funds. One of them is your warm intro.

Wesley Chanunlockedknows Detlev Biniszkiewicz · together at Massachusetts Institute of Technology (overlapped)

knows the team · via Harvard Business School

×4knows the team · via Massachusetts Institute of Technology

knows the team · via Blueprint Medicines

knows the team · via Atlas Venture

knows the team · via Arthur D. Little

✨ Fox Verdict

Investment thesis

MPM BioImpact leverages three decades of biotech venture expertise combined with impact investing principles to support companies across all drug development phases. The firm invests in both private and public biotech companies that aim to meaningfully improve patient outcomes and transform treatment of disease, while maintaining commitment to global impact investment standards.

Invests inBiotech Healthtech Impact & Social Good Longevity Mental Health Asia-Pacific Boston Global North America

Source: firm website, verified Sep 15, 2026.

Stage

Pre-Seed–Late Stage

Check

$1M – $15M

Boston, Massachusetts, US

Instruments

Equity

Founded

1992

Last 12 months

6 investments

AUM

$3.6B

Tracked investments

Unicorns

IPOs

Acquisitions

Team · 50 people

from the firm's website & curated & public directories

Ansbert Gadicke, M.D.· Chairman· Boston, Massachusetts, United Statesin

Chairman of MPM BioImpact with medical doctorate, involved in identifying and leading transformative therapeutic investments.

Detlev Biniszkiewicz· Managing Director· Boston, Massachusettsin

Managing Director and serial entrepreneur with deep expertise in oncology and immuno-oncology. Recently served as CEO of portfolio company NextPoint Therapeutics and currently chairs its Board. Previously President and CEO of Surface Oncology and held strategic roles at AstraZeneca and Novartis.

Ansbert K. Gadicke· Managing Partner· Boston, Massachusettsin

Managing Partner and founder of MPM Capital in 1992 as a biotech venture capital firm. Led investments in major successes including BioMarin Pharmaceuticals, Pharmasset (acquired by Gilead), and Cullinan Therapeutics. Recipient of 2017 Global Oncology Visionary Award.

a•••@mpmcapital.comreveal

Chris Bardon· Managing Partner· United States

Managing Partner at MPM BioImpact who led the firm's early public investment in argenx.

Chris Bardon, M.D.· Managing Partner

Managing Partner at MPM BioImpact with medical background, involved in early investment identification and portfolio strategy.

Christiana Bardon· Managing Partner· Massachusettsin

Christiana (Chris) Bardon is Managing Partner of MPM BioImpact, where she leads the firm's public market investing as portfolio manager for BioImpact Equities and the Oncology Impact Funds. She began her career as an analyst at MPM BioImpact and later worked as a health care analyst at Fidelity Investments covering biotechnology, life-science tools, and diagnostics. Trained as a physician, she earned her M.D. from Harvard Medical School and completed a residency in Internal Medicine at Brigham and Women's Hospital. She holds several academic and nonprofit roles, including Executive Fellow at Harvard Business School and Trustee of the American Association for Cancer Research Foundation.

c•••@mpmcapital.comreveal

Kristen Laguerre· Partner· Boston, Massachusettsin

Kristen Laguerre is an Executive Partner at MPM BioImpact with more than 25 years of financial leadership and management experience in venture capital. She joined the firm in 2017 and previously served as its Chief Operating Officer and Chief Financial Officer, and stepped in as interim CFO at portfolio companies ReNAgade Therapeutics and Cullinan Therapeutics. Before MPM BioImpact, she held CFO and partner roles at Atlas Venture and Flare Capital Partners, and led finance and operations as VP of Finance at Softbank Capital. Her current focus is managing the firm's Investment Committees, overseeing investment processes and portfolio construction.

Rami Rahal· Partner· San Francisco, California, United Statesin

Partner responsible for investment identification and due diligence of public equities. Spent majority of career in drug discovery for precision oncology and immunotherapy, most recently as Senior Director of Cancer Biology at Scorpion Therapeutics. Ph.D. from MIT in Genetics.

Todd Foley· Managing Director· Boston, Massachusettsin

Managing Director who joined the firm in 1999. Serves as Chairman of multiple portfolio company boards and has guided significant M&A outcomes including Semma Therapeutics acquisition by Vertex for $950M and Selexys acquisition by Novartis for $665M.

t•••@mpmcapital.comreveal

Wu Jie· Head of APAC

Head of APAC region focusing exclusively on early-stage investment and company creation opportunities. Previously spent 16 years at Temasek, most recently as Director of Life Sciences Investment, investing in healthcare companies including Juno Therapeutics and Guardant Health.

Melissa Rudd· Partnerin

Bard Geesaman· Managing Partner· United Statesin

Dan Hicklin· Managing Partner

David Stack· Managing Partner· Parsippany, New Jersey, United Statesin

Ed Hurwitz· Managing Director· Athertonin

Greg Sieczkiewicz· Managing Partner

Mitchell Finer· Managing Partner

Pablo Cagnoni· Managing Partner

Patrick Baeuerle· Managing Partner· Greater Munich Metropolitan Areain

Tony Rosenberg· Managing Director· Binningen, Basel-Country, Switzerlandin

Binsen Li· Principal· New York, New York, United Statesin

Principal responsible for investment identification, due diligence, and company creation in the APAC region. Previously spent five years at Hillhouse Capital covering global healthcare investments. Ph.D. research focused on amyloid fibrils in Parkinson's disease using cryo-electron microscopy.

David Kolesky· Principal· Boston, Massachusettsin 𝕏

Principal responsible for driving investments and company creation activities. Previously Principal at Flagship Pioneering where he co-founded Senda Biosciences and Montai Health. Completed postdoctoral fellowship at the Wyss Institute for Biologically Inspired Engineering at Harvard.

David Moskowitz· Principal· Boston, Massachusettsin

Principal focused on early-stage investments and company creation activities. Previously spent seven years at 8VC where he co-led the life sciences practice, co-founding several companies and serving on multiple boards. Ph.D. research focused on statistical and machine learning approaches for genomics data.

d•••@mpmcapital.comreveal

Victor Rusu· Principal· Boston, Massachusettsin

Principal focusing on private investments and new company formation. Previously Principal at Apple Tree Partners where he contributed to starting eight biotech companies. Founding scientist at Jnana Therapeutics and member of biotech equity research team at Citigroup.

Elaine Sun· Director - Business Development & Investor Relations· United Statesin

Vinay Bhaskar· Principal

Sebastian Meier-Ewert· Venture Partner

William Greene· Venture Partner· South San Francisco, California, United Statesin

William Greene is Chief Investment Officer at Hevolution Foundation. He brings experience across biotechnology investment, operational leadership, and clinical development, including roles as CEO of two life sciences startups and board positions at venture capital firms. His background encompasses neuroscience and epidemiology research, clinical program leadership, and global venture capital investing.

Andrew Scharenberg· Entrepreneur Partner

Entrepreneur Partner and founder/CEO of portfolio company Umoja Biopharma. Previously Attending Physician at Seattle Children's Hospital and Professor in Department of Pediatrics at University of Washington School of Medicine. Chief Scientific Officer at Cellectis Therapeutics and co-founder of Pregenen Inc.

Aparna Parikh· Entrepreneur Partner

Entrepreneur Partner and co-founder/CEO of Reversing Early Recurrence. Serves as Director of the Massachusetts General Hospital Global Cancer Care Program and Co-Director of GI Cancer Program. Associate Professor of Medicine at Harvard Medical School and gastrointestinal oncologist.

Brendan Furey· Chief Compliance Officer· Boston, Massachusetts, United Statesin

Chief Compliance Officer of the firm. Previously served as Senior Principal Consultant at ACA Group supporting venture capital and private equity funds in developing compliance programs. Licensed attorney with the Commonwealth of Massachusetts.

Brian Shuster· Entrepreneur Partner

Entrepreneur Partner serving on the board of NextPoint Therapeutics. Previously Chief Business Officer at Orna Therapeutics and ReNAgade Therapeutics. Senior Vice President of Corporate Development at Bristol Myers Squibb and Vice President of Business Development at Johnson & Johnson.

Briggs Morrison· Entrepreneur Partner· Newtown, Pennsylvania, United Statesin

Entrepreneur Partner and CEO of portfolio company Crossbow Therapeutics. Served as Chief Medical Officer and Executive Vice President for Global Medicines Development at AstraZeneca with experience overseeing clinical development at Pfizer and Merck.

Carolyn Bertozzi· Chairperson, Medical and Scientific Advisory Board

Chairperson of the Medical and Scientific Advisory Board. Anne T. and Robert M. Bass Professor of Chemistry at Stanford University and Howard Hughes Medical Institute Investigator. 2022 Nobel Prize laureate in Chemistry for founding the field of bioorthogonal chemistry. Founded 12 biotechnology companies through her academic research.

Chasen Richter· Head of Fund Investor Relations and Strategic Finance

Head of Fund Investor Relations and Strategic Finance leading fundraising and investor engagement initiatives. Previously Senior Director at Flagship Pioneering focusing on capital formation across life sciences venture creation funds and investor relations head at Moderna.

Christian Desmarteaux· Director of Investor Relations· Boston, Massachusetts, United Statesin

Director of Investor Relations responsible for coordinating existing and prospective investor relations efforts. Previously worked at Turbonomic, a Boston-based technology firm, and raised capital for privately held companies.

Christopher Wolf· Chief Financial Officer· Boston, Massachusetts, United Statesin

Chief Financial Officer overseeing the firm's finance functions. Brings 20+ years of CFO experience at alternative investment firms including Lincoln Peak Capital and HighVista Strategies. Previously Manager of Investment and Treasury Operations at Williams College.

Elizabeth Stoner· Entrepreneur Partner· Seattle, Washington, United Statesin

Entrepreneur Partner serving as Senior Clinical Advisor to Rhythm Pharmaceuticals. Brings decades of international biopharma industry experience including interim CEO of Semma Therapeutics and founding CMO/CDO of Rhythm. Previously Senior Vice President of Global Clinical Development Operations at Merck.

Frank Neumann· Entrepreneur Partner

Entrepreneur Partner and Acting Chief Medical Officer of portfolio company K2 Therapeutics. Brings extensive experience in cell therapy and oncology clinical development. Previously Senior Vice President and Global Head of Clinical Development at Kite, a Gilead Company.

Gisella de la Rocha· Vice President of Legal· San Francisco, California, United Statesin

Vice President of Legal at the firm. Previously worked at 5AM Ventures and Moderna advising on complex licensing transactions and strategic M&A. Began legal career at Kirkland & Ellis LLP focusing on private equity and public company M&A.

Grey Sieczkiewicz· IP Counsel

IP Counsel serving several portfolio companies. Previously IP strategy architect for venture-backed life sciences companies and Vice President, IP at Flagship Ventures. Practiced patent counseling at national law firms Mintz Levin, Proskauer Rose, and Foley Hoag.

Luke Evnin· Advisor· Californiain 𝕏

Co-founder of the predecessor company MPM Capital in 1997 and Advisor to the firm. Served as interim CEO of publicly traded Werewolf Therapeutics and co-founded seven MPM portfolio companies including Blade Therapeutics, Harpoon Therapeutics, and Tizona Therapeutics over a 30+ year venture capital career.

Matthew Roden· Entrepreneur Partner

Entrepreneur Partner and CEO of portfolio company Aktis Oncology. Previously held senior leadership roles at Bristol Myers Squibb as Senior Vice President and Head of Enterprise Strategy. Earlier served as Head of Biotechnology Equity Research at UBS Investment Bank.

Michael Ehlers, M.D.· Board Member

Pankaj Bhargava· Entrepreneur Partner

Entrepreneur Partner and CEO of portfolio company Ashibio. Brings over two decades of drug development experience including roles at Gilead Sciences as Vice President and Head of Oncology Therapeutic Area, and previously served as Chief Medical Officer at Dicerna Pharmaceuticals.

Robert Risoleo· General Counsel

General Counsel of the firm. Previously spent 35 years at Sullivan and Cromwell LLP as a trusted advisor on novel and complex transactions including capital markets, M&A, joint ventures, and corporate restructuring. J.D. from Yale Law School.

Sam Goldman· Senior Associate

Senior Associate responsible for investment identification and due diligence of public equities. Previously a fellow with the firm surveilling scientific fields. Completed Ph.D. in Computational and Systems Biology at MIT focusing on AI/ML methodologies for analyzing molecular data.

Alan Kelly· Director

Nicole Ramroop· Director

Hao Xing· Associate

h•••@mpmcapital.comreveal

Founder mafia

The MPM BioImpact mafia →

11 people who came through MPM BioImpact went on to found or lead other companies.

Luke EvninAdvisorFounded Mpmcapital +1 Briggs MorrisonEntrepreneur PartnerFounded Crossbow Therapeutics +1 Brian GoodmanPartnerFounded Evelo Biosciences +1 William GreeneVenture PartnerFounded Pear Therapeutics +1 Detlev BiniszkiewiczManaging DirectorFounded NextPoint Therapeutics Todd FoleyManaging DirectorFounded Aktis Oncology David KoleskyPrincipalFounded Montai Therapeutics Andrew ScharenbergEntrepreneur PartnerFounded Umoja Biopharma, Inc.Ansbert Gadicke, M.D.ChairmanFounded Mpmcapital Patrick BaeuerleManaging PartnerFounded Aktis Oncology Dan HicklinManaging PartnerFounded Werewolf Therapeutics

What they invest in

from 56 of 66 portfolio companies

Biotech ×52Healthtech ×23Medical Devices ×14AI & Machine Learning ×6Digital Health ×6Deep Tech ×4Longevity ×3Consumer ×1

HQs:United States×47United Kingdom×1

Who they back

founder profiles across 12 portfolio companies

50%

solo founders

6 of 12 mapped founding teams

50%

repeat founders

of 12 founders with career history

~3 yrs

old at investment

median across 8 dated deals

Founding team size:solo founder×62 founders×33 founders×14+ founders×2

Where their founders worked beforefrom 12 founders with career history

Longwood Fund ×3Harvard Medical School ×2Longwoodfund ×2Maverick Therapeutics ×2Mpmcapital ×2Potenza Therapeutics ×2Trieza Therapeutics ×2Vesuvius Pharmaceuticals ×2

Investments · 66 tracked

founders shown can be your intro path

By year:2026 · 3 2025 · 5 2024 · 4 2023 · 2 2022 · 2 2021 · 4 2020 · 5 2019 · 5 2018 · 4 2017 · 3 2016 · 4 2015 · 250 dated

Aktis Oncologyaktisoncology.com inNASDAQ: AKTSSeries A · Oct 2024 · $318M

Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.

BiotechHealthtechMedical DevicesBoston, US

Todd Foley(Co-founder and Chairman)in Patrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)in Paul L. Feldman(Chief Scientific Officer)in

Board seat Todd Foley· per SEC Form D

Co-investorsAndreessen Horowitz EcoR1 Capital MRL Ventures Fund Pappas Capital RA Capital TCG Crossover +5 more

Entrada Therapeutics, Inc.entradatx.com inNASDAQ: TRDAApr 2021

Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.

BiotechHealthtechBoston, US

Natarajan Sethuraman(Executive Officer)in Nerissa Kreher(Executive Officer)in Kory Wentworth(Executive Officer)in Dipal Doshi(Chief Executive Officer)in Nathan Dowden(Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)

Board seat Todd Foley· per SEC Form D

Co-investors5AM Ventures Agent Capital MRL Ventures Fund Roche Venture Fund TCG Crossover

Dyne Therapeuticsdyne-tx.com in 𝕏NASDAQ: DYNAug 2020

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)inOxana Beskrovnaya, Ph.D.(Executive Officer)John G. Cox(Chief Executive Officer and President, Director)in

Co-investorsAtlas Venture Vida Ventures Forbion Hercules Capital, Inc.RA Capital

Syndax Pharmaceuticals inNASDAQ: SNDX

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company that develops and commercializes small-molecule and antibody cancer therapies, including two FDA-approved medicines: revumenib (a menin inhibitor for acute leukemias) and axatilimab (a CSF-1R blocking antibody for graft-versus-host disease and fibrotic diseases), along with clinical-stage programs exploring expanded uses and combinations in oncology.

BiotechWaltham, US

John Pallies(Executive Officer)in Arlene Morris(Executive Officer, Director)in Michael A. Metzger(Chief Executive Officer)in Keith A. Goldan(Chief Financial Officer)in

Board Dennis Podlesak(Director)inIvor Royston(Director)

Co-investorsForesite Capital Pappas Capital Sofinnova Ventures venBio Partners BlackRock Domain Associates

Umoja Biopharma, Inc.umoja-biopharma.com in 𝕏Series A · Jun 2021 · $53M✓ verified

Umoja Biopharma develops in vivo CAR T cell cancer therapies using its VivoVec platform, which generates chimeric antigen receptor T cells directly inside a patient's body rather than through the traditional ex vivo process.

BiotechHealthtechSeattle, US

Andrew M. Scharenberg(Executive Officer, Director)Philip S. Low(Director)

BoardIrena Melnikova(Executive Officer)Anna French(Director)Robert Glassman(Director)John Hamer(Director)in

Board seat Luke Evnin· per SEC Form D

Co-investorsDCVC Bio Qiming Venture Partners USA SoftBank Group K2 HealthVentures SoftBank Vision Fund DCVC (Data Collective)

Arialysarialysrx.com in 𝕏✓ verified

Arialys Therapeutics develops precision medicines designed to block pathogenic autoantibodies that target brain receptors such as the NMDA receptor, aiming to treat neuropsychiatric disorders driven by autoimmune disease.

BiotechHealthtechLa Jolla, US

Peter Flynn, Ph.D.(Executive Officer, Director)

BoardJay Lichter, Ph.D.(Director)Brian Slingsby, M.D., Ph.D., M.P.H.(Director)Ed Hurwitz(Director)inAshish Xavier, Ph.D.(Director)Tighe Reardon(Executive Officer)

Co-investorsAvalon BioVentures Catalys Pacific

Fablefabletherapeutics.com✓ verified

Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.

BiotechHealthtechLongevity

Geoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)

Co-investorsVersant Ventures DCVC Bio Lilly Asia Ventures DCVC (Data Collective)

Photys Therapeutics, Inc.photys.com inSeries A · Sep 2022 · $75M✓ verified

Photys Therapeutics develops bifunctional small-molecule medicines that use induced proximity to recruit kinases and drive targeted protein phosphorylation, aiming to modulate and repair disease-driving proteins.

BiotechHealthtechLongevityWaltham, US

Amit Choudhary(Scientific Founder)David Steinberg(Chairman & Founding CEO)inEdward Holson(Co-founder & CSO)in Lizzie Ngo(Co-founder)inBrian Fenton(President & CEO)in

Co-investorsLongwood Fund 8VC MRL Ventures Fund Ono Venture Investment, Inc.

Tizona Therapeutics, Inc.tizonatx.com✓ verified

Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.

AI & Machine LearningBiotechHealthtech

Vijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)Christine O'Brien(Chief Executive Officer & Board Member)inCourtney Beers(Chief Scientific Officer)

Co-investorsCanaan Partners Abingworth Gilead Sciences Astellas Venture Management LLC Lightstone Ventures

Trishula Therapeutics, Inc.trishulatx.com in✓ verified

Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers.

BiotechHealthtech

Anil Singhal(President and CEO)inSiddhartha Mitra(Chief Medical Officer)in

Co-investorsCanaan Partners Astellas Venture Management LLC Lightstone Ventures

Vascular Pharmaceuticalsvascularpharma.comDec 2015✓ verified

Vascular Pharmaceuticals develops VPI-2960B, a therapeutic candidate in clinical development for diabetic nephropathy treatment.

BiotechDigital HealthMedical DevicesChapel Hill, US

Laura Maile(Co-Founder, Director, Research and Development)Richard Shea(Executive Officer, Director)inBonnie Layman(Executive Officer)David Clemmons(Co-Founder, Chief Scientific Officer)

Board Elizabeth Stoner(Director)inRichard Kent(Director)

Chiasmachiasmapharma.comSeries C · Dec 2014 · $44M

BiotechNewton Centre, US

Chaime Orlev(Executive Officer)Roni Mamluk(Executive Officer, Director)

BoardScott Minick(Director)in Todd T. Foley(Director)inVincent Miles(Director)

Board seatBard GeesamanDavid Stack Ansbert K. Gadicke· per SEC Form D

Co-investorsHEALTHCARE ROYALTY PARTNERS Sofinnova Ventures Abingworth ARCH Venture Partners

Clinical inkclinicalink.com in 𝕏Dec 2017 · $20M

Clinicalink offers a digital tool designed to improve drug adherence and measure the functional quality of weight loss.

Digital HealthHealthtechSaaSWinston-Salem, US

Douglas E. Pierce, Jr.(Executive Officer, Director, Promoter)Joe Schmidt(Executive Officer)Edward S. Seguine(Executive Officer, Director, Promoter)

Board Ansbert Gadicke(Director)in Matt King(Director)inBrad Geesaman(Director)

Board seat Tony Rosenberg Todd Foley Ansbert K. Gadicke· per SEC Form D

Co-investorsFCA Venture Partners McKesson Ventures

Crossbow Therapeuticscrossbowtx.com inSeries A · Sep 2025 · $77M

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Alexander Nolte(Executive Officer)in Dmitri Wiederschain(Executive Officer)in

Board Alexandra Cantley(Director)inSakae Asanuma(Director)in Briggs Morrison(Executive Officer, Director, Promoter)in Irena Melnikova(Director)in

Board seat Todd Foley· per SEC Form D

Co-investorsPfizer Venture Investments Biotechnology Value Fund Mirae Asset Venture Investment Pfizer Ventures Polaris Partners Taiho Ventures, LLC

Frontier Medicinesfrontiermeds.com in 𝕏Jun 2021 · $80M

Frontier is a drug discovery company developing small-molecule covalent drugs aimed at previously undruggable protein targets across the proteome.

AI & Machine LearningBiotechSouth San Francisco, US

Chris Varma, Ph.D.(Executive Officer, Director)Chris Varma(Co-founder, Chairman and CEO)inJim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)inGregory Chow(Executive Officer)

Board seat Luke Evnin· per SEC Form D

Co-investorsBerkeley Catalyst DCVC (Data Collective)Droia Ventures RA Capital DCVC Bio Deerfield Management Company

Harpoon Therapeuticsharpoontx.com in 𝕏Series B · Nov 2018 · $45M

A research-intensive biopharmaceutical company that develops medicines and vaccines.

BiotechHealthtechSouth San Francisco, US

Luke Nathaniel Walker(Executive Officer)Julie Eastland(Executive Officer, Director)in

BoardRonald Hunt(Director)Mark Chin(Director)Alan Colowick(Director)Jonathan Drachman(Director)

Board seat Patrick Baeuerle Luke EvninPablo CagnoniDan Hicklin· per SEC Form D

Co-investorsK2 HealthVentures Taiho Ventures, LLC Arix Bioscience Lilly Asia Ventures New Leaf Venture Partners OrbiMed

NextPoint Therapeuticsnextpointtx.com in 𝕏Series B · Feb 2024 · $42.5M

NextPoint is a precision therapeutics company developing cancer treatments targeting the B7-H7/HHLA2 axis, including a T-cell engager, an antibody-drug conjugate with proprietary linker technology, and a multi-functional checkpoint inhibitor.

BiotechHealthtechAustin, US

Gordon Freeman(Scientific Founder)XingXing Zang(Scientific Founder)in Ivan Cheung(Chief Executive Officer)in Leena Gandhi(Chief Medical Officer)in Tatiana Novobrantseva(Chief Scientific Officer)inAxel Hoos(Director)

Board seat Detlev Biniszkiewicz· per SEC Form D

Co-investorsCatalio Capital Management, LP Sanofi Ventures Catalio Capital Management Invus Leaps by Bayer Sixty Degree Capital

Oncorus inSeries A · Mar 2016 · $57M

Cambridge, US

Christophe Queva(Executive Officer)inTheodore Ashburn(Executive Officer, Director)Alon Lazarus(Director)Cameron Wheeler(Director)in

Board seatMitchell Finer Luke Evnin Briggs Morrison· per SEC Form D

Co-investorsAstellas Venture Management LLC Cowen Healthcare Investments Deerfield Management Company IMM Investment K2 HealthVentures Sphera Funds Management

Reunion Neurosciencereunionneuro.com in 𝕏Series A · Sep 2025 · $103M

Reunion Neuroscience is a clinical-stage biopharmaceutical company developing serotonergic psychedelic therapies for mental health conditions such as postpartum depression, adjustment disorder, and generalized anxiety disorder.

BiotechDigital HealthMental HealthMorristown, US

Sahil V. Kirpekar(President and CEO)inGregory Mayes(Executive Officer, Director)Ellen Lubman(Director)Mark Pollack(Executive Officer)inNathan Bryson(Executive Officer)in Mark Theeuwes(Executive Officer)in

Board seat Ansbert K. Gadicke· per SEC Form D

Co-investorsFemHealth Ventures Mitsui Global Investment Novo Holdings

Werewolf Therapeuticswerewolftx.com inSeries A · Dec 2020 · $56M

Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.

BiotechHealthtechMedical DevicesWatertown, US

Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))inDaniel Hicklin(Executive Officer, Director)David Cordo(Executive Officer)Alon Lazarus(Director)

Board Christoph Westphal(Director)

Board seat Luke Evnin Briggs Morrison· per SEC Form D

Co-investorsDC Investment Partners K2 HealthVentures Longwood Fund RA Capital Taiho Ventures, LLC

0 2 AstronauTxastronautx.bio in

AstronauTx is a biotechnology company focused on drug discovery and development for neurodegenerative and neuroinflammatory diseases, working across small molecules and biologics.

BiotechDeep TechHealthtechLongevityMedical Devices

Jane Rhodes(Chief Executive Officer)inMagnus Ivarsson(Chief Scientific Officer)inHannah Pearce(Chief Operating Officer)inMichelle L. Mellion(Chief Medical Officer)in

Co-investorsNovartis Venture Fund SV Health Investors UCL Technology Fund AlbionVC

Alestaalestatherapeutics.com inSeries A · Jan 2025 · $67M

Alesta Therapeutics develops therapies for rare diseases, with research focused on genetic diseases and oncology.

BiotechHealthtech

Ilan Ganot(CEO)inBenit Maru(CMO)Matthias Van Woensel(CSO)in

Co-investorsDroia Ventures Frazier Life Sciences Novartis Venture Fund Frazier Healthcare Partners RTW Investments L.P.Thuja Capital

Anokionanokion.comSeries B · Sep 2019 · $40M

Co-investorsVersant Ventures Vivo Capital

Antiva Biosciencesantivabio.com in

Antiva Biosciences develops a topical therapeutic for women with high-risk HPV infection and pre-cancerous cervical lesions, utilizing antiviral prodrug chemistry.

BiotechFemTechHealthtechMedical DevicesRedwood City, US

Karl Y. Hostetler(Executive Officer, Director)in Gail Maderis(Director)in Kristine Ball(President & CEO)in Elaine Chien(Executive Officer)inSarah Walter(Executive Officer)in Raju Gadiraju(Executive Officer)in

Co-investorsAdjuvant Capital Brace Pharma Canaan Partners Lumira Ventures OUP (Osage University Partners)Sofinnova Ventures +3 more

argenxargenx.com

The company develops therapies for people with severe autoimmune diseases.

BiotechHealthtechMedical Devices

Co-investorsAvoro Capital Advisors PMV

AshiBioashibio.com in

āshibio is a biotech company developing novel therapies for rare bone and connective tissue disorders, led by a team of scientists, physicians and drug developers.

BiotechHealthtechBurlingame, US

Pankaj Bhargava(Founder & Chief Executive Officer)inVictoria Smith(Chief Scientific Officer)Deborah Wenkert(Chief Medical Officer)inJoseph Sarret(Acting Chief Operating Officer)Brian Shuster(Acting Chief Business Officer)

Co-investorsAgent Capital

Cullinan Oncologycullinanoncology.com in 𝕏

Cullinan Therapeutics develops clinical-stage T cell engager therapies targeting autoimmune diseases and cancer, leveraging immune modulation expertise to advance high-impact therapeutic candidates.

BiotechDigital Health

Co-investorsLAV Lilly Asia Ventures Schooner Capital Taiho Ventures, LLC

Deka Biosciencesdekabiosciences.comSeries B · Sep 2023 · $20M

BiotechGermantown, US

John Mumm(Executive Officer, Director)Vera Mumm(Executive Officer)Pavel Khrimian(Executive Officer, Director)Lucio Iannone(Director)Sally (Yuanheng) Wang(Director)

Board Lu Han(Director)in

Co-investorsLumira Ventures Plains Ventures Echo Investment Capital Leaps by Bayer

elevatebioelevate.bio in 𝕏Series A · May 2019 · $150M

ElevateBio is a contract development and manufacturing organization (CDMO) for advanced therapies, offering discovery, process development, analytics, manufacturing, and regulatory support for cell therapies, viral vectors, mRNA therapeutics, and gene editing.

BiotechDeep TechHealthtechWaltham, US

David Hallal(CEO)inMike Paglia(Chief Technology Officer)Ger Brophy(CEO)in

Co-investorsEcoR1 Capital Samsara BioCapital SoftBank Vision Fund

Epi Biologicsepibiologics.com inSeries B · Jan 2026 · $110M

Epibiologics develops protein degradation medicines using protein sciences and antibody engineering capabilities.

BiotechMedical DevicesSan Mateo, US

Ann Lee-Karlon(Executive Officer, Director)inMitchell Mutz(Executive Officer, Director)James Wells(Director)

Board Samuel Bjork(Director)in Alexandra Cantley(Director)in Seiji Miyahara(Director)in

Co-investorsAvego BioScience Capital GV (Google Ventures)Mission Biocapital Novartis Venture Fund Roche Venture Fund Samsara BioCapital +4 more

Fireflyfireflybiologics.com in

Firefly Bio develops antibody-drug conjugates (ADCs) that use novel classes of payloads, drawing on a research team experienced in ADC discovery and development.

BiotechHealthtechMedical Devices

Scott Hirsch(CEO)inDan Kaplan(CSO)

Co-investorsDecheng Capital

Immunitas Therapeuticsimmunitastx.com inSeries A · Nov 2019 · $39M

Immunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies.

BiotechDigital HealthMedical DevicesWaltham, US

Amanda Wagner(Executive Officer)Dan Matloff(Executive Officer)Jiaping Gu(Director)Jeffrey Goldberg(Executive Officer, Director)

Board Laura Brass(Director)in Kai Wucherpfennig(Director)

Co-investorsAgent Capital DC Investment Partners Longwood Fund Medical Excellence Capital Novartis Venture Fund Ono Venture Investment, Inc.+3 more

K2k2space.com in 𝕏Aug 2026 · $50M

K2 Space designs and builds satellite hardware and subsystems — including power, propulsion, autonomy, thermal, and structures — for space missions such as multi-orbit constellations, deep space relay, and large-scale observatories.

Deep TechHardwareSpace Tech

Karan Kunjur(CEO, Co-Founder)inNeel Kunjur(CTO, Co-Founder)in

Co-investorsAlpine Space Ventures CapitalG First Round Capital ICONIQ Kleiner Perkins LG Technology Ventures +11 more

K2k2tx.com

K2 Therapeutics is a biotech company that identifies innovative drug assets and develops them into medicines using a hub-and-spoke model with cross-regional clinical trials.

BiotechHealthtech

Co-investorsAlpine Space Ventures Altimeter Capital CapitalG ICONIQ Kleiner Perkins Lightspeed Venture Partners +4 more

Ornaornatx.com inSeed · Jan 2020 · $20M

Orna Therapeutics develops RNA and lipid nanoparticle (LNP) based therapies for treating diseases including oncology and cell therapy applications.

AI & Machine LearningBiotechMedical Devices

Joe Bolen(Chief Executive Officer)Joe Bolen, Ph.D.(Chief Executive Officer)Hope D'Oyley-Gay, JD(Chief Legal Officer)Ciaran Lawlor, Ph.D.(Chief Operating Officer)Frank Neumann, M.D., Ph.D.(Chief Medical Officer)Siva Sakhamuri(Chief Technology Officer)in

Co-investorsAstellas Venture Management LLC Taiho Ventures, LLC

Protego Biopharmaprotegobio.com inDec 2025 · $130M

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US

Brent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)

BoardTIM LOHOFF(Director)Edward Hurwitz(Director)

Co-investorsDroia Ventures Novartis Venture Fund Digitalis Ventures Forbion Lightspeed Venture Partners Vida Ventures +1 more

ReCode Therapeuticsrecodetx.com in 𝕏

ReCode develops mRNA and gene correction therapeutics for genetic diseases, using proprietary lipid nanoparticle technology to deliver treatments to specific organs.

AI & Machine LearningBiotechHealthtechMedical DevicesMenlo Park, US

Dr. Daniel J. SiegwartArthur E Johnson(Executive Officer, Director)

Co-investorsAju IB Invesment Corporation EcoR1 Capital Evolution VC Partners OrbiMed OUP (Osage University Partners)Pfizer Venture Investments +6 more

Selexys Pharmaceuticals in

BiotechOklahoma City, US

Scott Rollins, Ph.D.(Executive Officer, Director)David Falconer(Executive Officer)inRichard Alvarez(Executive Officer)inRussell Rother(Executive Officer)inRodger McEver, M.D.(Director)

BoardPhilip Jones, M.D.(Director)

Semma Therapeuticssemma-tx.comacquired by Vertex Pharmaceuticals · Sep 2019 · $950M

Cambridge, MA biotech developing stem cell-derived islet therapy plus an immune-protective device for type 1 diabetes; acquired by Vertex for $950M.

BiotechCambridge, US

Robert Millman(Executive Officer, Director)

Board Todd Foley(Executive Officer, Director)inMitch Finer(Director)Stephen Knight(Director)inJim Scopa(Director)William Sahlman(Director)

Co-investorsARCH Venture Partners F-Prime Capital JDRF T1D Fund ORI Capital Slater Technology Fund Eight Roads Ventures

SiO2 Medical Productssio2ms.comNov 2019

SiO2 Materials Science develops precision molded polymer containers with thin glass-like barrier coatings for pharmaceutical and biopharmaceutical applications.

BiotechMedical DevicesNew MaterialsAuburn, US

Robert S. Abrams(Executive Officer, Director)inRobert Pangborn(Director)John Belfance(Director)Jean-Marie Painvin(Director)Thomas Strungmann(Director)Jared Morris(Director)

Valeritasvaleritas.com inJun 2014

An Italian-language affiliate guide that reviews and ranks non-AAMS online casinos (foreign-licensed gambling sites) accessible to Italian players, comparing bonuses, game catalogs, payment methods, and licensing.

ConsumerGamingMedia & EntertainmentBridgewater, US

William Duke(Executive Officer)inKristine Peterson(Executive Officer, Director)

BoardDaniel Pelak(Director)Sean Traynor(Director)Ittai Harel(Director)inPaul Queally(Director)

Co-investorsAgate Medical Investments LP HLM Venture Partners Kaiser Permanente Ventures Abingworth Pitango Welsh, Carson, Anderson & Stowe

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Amphivena Therapeutics BioIntervene Blade Therapeutics Firefly Bio, Inc.HotKnot Therapeutics, Inc.Maverick Therapeutics Moat Biotechnology Potenza Therapeutics Redona Therapeutics, Inc.Rekindle Therapeutics Tetherex Pharmaceuticals Corp Trieza Therapeutics Vesuvius PharmaceuticalsāshibioCoDa Therapeutics Iconic Therapeutics Idun Pharmaceuticals iTeos TherapeuticsK2 TherapeuticsNeoVistaProtegoRadius HealthReNAgade TherapeuticsReunionTCR2

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.

Exits · 5

4 IPOs · 1 acquisitions

Aktis OncologyNASDAQ: AKTSEntrada Therapeutics, Inc.NASDAQ: TRDADyne TherapeuticsNASDAQ: DYNSyndax PharmaceuticalsNASDAQ: SNDXSemma Therapeuticsacq. by Vertex Pharmaceuticals

Portfolio news

latest coverage across their companies

argenx at Morgan Stanley conference: broadening beyond vyvgart By Investing.com

argenx · investing.com · Sep 14, 2026

AI workload optimization startup Callosum raises $100M - SiliconANGLE

Firefly · siliconangle.com · Aug 20, 2026

Etched's $21b valuation, Smack's battlefield software, and Goldman's real estate buy

Alesta · axios.com · Aug 18, 2026

Singapore's biotechnology firm K2 Therapeutics raises $50M in seed financing from MPM BioImpact - TNGlobal

K2 · technode.global · Aug 12, 2026

Syndax (SNDX) Q2 2026 Earnings Call Transcript - AOL

Syndax Pharmaceuticals · aol.com · Aug 12, 2026

K2 Space Raises $500M Series D to Scale High-Power Satellites

K2 · latimes.com · Aug 11, 2026

Single-nucleus multimodal spatial transcriptomics reveals spatial colocalization of neoantigen-expressing tumor cells and cognate T cells | Nature Biotechnology

NextPoint Therapeutics · nature.com · Jul 22, 2026

Venture funding drops in Seattle area as AI boom reshapes startup world – GeekWire

ReCode Therapeutics · geekwire.com · Jul 13, 2026

IPO stake values · per SEC filings · 3

Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.

Company	Owned	IPO price	At IPO	Stake value
Aktis Oncology	17.4%	$18.00	Jan 2026	$164.7M
Entrada Therapeutics, Inc.	14.4%	$20.00	Nov 2021	$86.5M
Syndax Pharmaceuticals	12.5%	$12.00	Mar 2016	$26M

Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).

Frequently asked questions

How many investments has MPM BioImpact made?: MPM BioImpact has 66 tracked investments, 5 of which have exited, including 9 dated in the last 24 months.
What stage does MPM BioImpact invest at?: MPM BioImpact invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
What is MPM BioImpact's typical check size?: MPM BioImpact typically writes checks of $1M – $15M.
What sectors does MPM BioImpact focus on?: MPM BioImpact focuses on Biotech, Healthtech, Impact & Social Good, Longevity, Mental Health.
Where is MPM BioImpact located?: MPM BioImpact is headquartered in Boston, US.
Does MPM BioImpact lead rounds?: MPM BioImpact has led 4 of the 11 rounds where its role is on record.
Who does MPM BioImpact co-invest with?: MPM BioImpact most often shares deals with Vida Ventures, Astellas Venture Management LLC, Canaan Partners, among 46 tracked co-investors.

Co-investors · 39

Novartis Venture Fund

The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.

Both backed · 6

0 2 AstronauTx Alesta CoDa Therapeutics Epi Biologics Immunitas Therapeutics Protego Biopharma

$5M – $25M

RA Capital

RA Capital is a multi-stage investment firm focused on healthcare, life sciences, and planetary health, investing across public and private markets and creating new companies through its Raven incubation platform.

Both backed · 5

Aktis Oncology Dyne Therapeutics Frontier Medicines iTeos Therapeutics Werewolf Therapeutics

OUP (Osage University Partners)

OUP (Osage University Partners) is a venture firm that invests in science-driven startups commercializing deep technology innovations emerging from university and breakthrough research.

Both backed · 4

Antiva Biosciences Blade Therapeutics Iconic Therapeutics ReCode Therapeutics

$1M – $20M

Versant Ventures

Versant Ventures operates in-house Discovery Engines staffed by multidisciplinary scientists in dedicated laboratory facilities to help launch new biotechnology companies alongside academic founders.

Both backed · 4

Fable Firefly Bio, Inc.NeoVistaAnokion

$250K – $5M

Deerfield Management Company

Deerfield Management is a healthcare-focused investment firm that supports companies across the healthcare ecosystem through flexible funding, market intelligence, and philanthropic initiatives.

Both backed · 3

Blade Therapeutics Frontier Medicines Oncorus

Abingworth

Abingworth is a life science venture capital firm that backs early-stage biopharma and biotech companies, helping entrepreneurs translate scientific discoveries into new therapeutics.

Both backed · 3

Chiasma Tizona Therapeutics, Inc.Valeritas

$15M – $30M

Pfizer Venture Investments

Pfizer Venture Investments is a strategic venture fund that doesn't require product or technology rights as a condition of investing, giving founders independence while still aiming for future collaboration with Pfizer, and its team blends venture investing with business development and drug discovery expertise to back frontier scientific bets—such as neuroscience, in-vivo cell engineering, dark-genome target discovery, and the blockchain-based longevity accelerator VitaDAO—that many biotech investors avoid. The fund also runs an active China strategy through a locally based venture vehicle and direct investments like OTR Therapeutics, and it has become a channel for strategic deals, with portfolio companies acquired by AbbVie, Ipsen, and Gilead/Kite.

Both backed · 3

Blade Therapeutics Crossbow Therapeutics ReCode Therapeutics

$5M – $20M

Leaps by Bayer

Both backed · 3

Deka Biosciences Immunitas Therapeutics NextPoint Therapeutics

Longwood Fund

Longwood Fund is a venture capital firm that creates and invests in novel healthcare companies developing new treatments for patients, drawing on its partners' company-building and operating experience.

Both backed · 3

Immunitas Therapeutics Photys Therapeutics, Inc.Werewolf Therapeutics

Agent Capital

Agent Capital is a healthcare venture capital firm that invests in novel, differentiated therapeutics and treatments addressing unmet patient needs across all stages of development.

Both backed · 3

Entrada Therapeutics, Inc.AshiBio Immunitas Therapeutics

MRL Ventures Fund

MRL Ventures Fund (MRLV) is the therapeutics-focused corporate venture group of MSD, backing early-stage, preclinical drug-development companies across all modalities with capital and scientific partnership.

Both backed · 3

Aktis Oncology Entrada Therapeutics, Inc.Photys Therapeutics, Inc.

$25M

GV (Google Ventures)

GV (Google Ventures) is a venture capital firm that has invested in artificial intelligence and machine learning since its early days, building a global portfolio of more than 100 AI companies across infrastructure, life sciences, and applications.

Both backed · 2

Antiva Biosciences Epi Biologics

$250K – $50M

▶27 more co-investors

Polaris Partners ARCH Venture Partners OrbiMed Digitalis Ventures Vivo Capital Andreessen Horowitz Kleiner Perkins 8VC Atlas Venture Frazier Healthcare Partners 6 Dimensions Capital Medical Excellence Capital Novo Holdings Catalio Capital Management, LP Bessemer Venture Partners Norwest Venture Partners Draper Fisher Jurvetson (DFJ)Third Point Ventures Earlybird Venture Capital Sofinnova Partners SR One Capital Management The Column Group Qiming Venture Partners Tencent Holdings Cofounders Capital Pureos Bioventures JMI Equity

Firms observed investing alongside MPM BioImpact, from public investor directories. Shared companies are the overlap with MPM BioImpact's recorded portfolio.

Similar investors

Equitage Ventures, L.L.C.

Equitage Ventures is an early-stage investor providing capital, distribution, and strategic guidance to entrepreneurs addressing the physical, mental, spiritual, and social needs of older adults across the senior care continuum.

Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.

$1.1M – $54M

Obvious Ventures

Obvious is a venture capital firm focused on supporting founders building solutions to humanity's largest challenges across planetary health, human health, and economic health.

$250K – $6M

LIFTT

LIFTT is a venture capital holding company focused on deep tech technologies, using an operational, multi-vertical approach aimed at generating impact. It works to transform scientific research into high-impact companies, accelerating the path from lab to market.